Related Experiment Videos
Combination therapy for osteoporosis: considerations and controversy
1University of Wisconsin-Madison, Osteoporosis Clinical Center and Research Program, 2870 University Avenue, Suite 100, Madison, WI 53705, USA. nbinkley@facstaff.wisc.edu
Current Rheumatology Reports
|March 12, 2005
Summary
Combination therapy for osteoporosis, using two drugs simultaneously, shows potential for bone mass increase but lacks proven fracture reduction benefits. Current evidence does not support its use due to increased costs and side effects.
Area of Science:
- Pharmacology
- Bone Metabolism
- Clinical Trials
Background:
- Osteoporosis management often involves single-agent therapy.
- Combination therapy aims to enhance fracture risk reduction.
- Current clinical interest is high in dual-agent approaches for osteoporosis.
Purpose of the Study:
- To review the rationale for combination therapy in osteoporosis.
- To summarize existing clinical trial data on combination treatments.
- To discuss the implications of combination therapy for fracture risk, cost, and adherence.
Main Methods:
- Literature review of clinical trials and scientific rationale.
- Analysis of data on bone mass changes with combined therapies.
- Evaluation of fracture risk reduction, cost, and side effect profiles.
Main Results:
- Antiresorber combinations (e.g., estrogen and bisphosphonates) increased bone mass more than monotherapy.
- Combining anabolic agents (e.g., parathyroid hormone) with bisphosphonates did not yield additive effects.
- No studies are sufficiently powered to confirm fracture risk reduction with combination therapy.
Conclusions:
- Combination therapy may increase bone mass but lacks demonstrated fracture reduction benefits.
- Increased costs, potential for more side effects, and reduced adherence are significant concerns.
- Currently, combination therapy for osteoporosis is not recommended due to insufficient evidence of efficacy and likely drawbacks.